Press releases

The press releases are available in Swedish when no translation exists.

Notice of Extraordinary General Meeting of Chordate Medical Holding AB (publ)

N.B. The English text is an in-house translated summary of the original Swedish text and should only be construed as a brief notification service to non-domestic shareholders. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

The shareholders of Chordate Medical Holding AB (publ) are hereby summoned to the Extraordinary General Meeting on October 5th, 2021.

Matters of the Extraordinary General Meeting are listed below. The notice in its entirety and postal voting form will be made available in English on the company website.

  1. Election of chairman
  2. Establishment and approval of the ballot paper
  3. Selection of one or two adjusters
  4. Examination of whether the Extraordinary General Meeting has been duly convened
  5. Approval of agenda
  6. Determination of fees to the board
  7. Election of a board member
  8. The Board's proposal for a long-term incentive program 2021
  9. Establishment of a nomination committee

For more information about the full Notice of Extraordinary General Meeting, please read the Swedish version (or the English version, when made available on the company website), or contact the company.

This disclosure was submitted for publication, through the contact person below, on September 20th, 2021, at 14:30 am CET.

For more information, please contact:

Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more at
https://www.chordate.com/en/

We are a Swedish medical technology company listed on NGM Nordic SME.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact